709 results about "IC50" patented technology

The invention provides a hybridoma cell line 1C11 and an anti-aflatoxin general monoclonal antibody secreted by the same as well as the applications thereof. The hybridoma cell line 1C11 can be used for preparing a high-titer aflatoxin antibody, and a mouse hydroperitoneum antibody is measured to reach 5.12*106 by using an ELISA (Enzyme-Linked Immunosorbent Assay). The anti-aflatoxin general monoclonal antibody has high sensitivity, respectively reaches the IC50 (50% inhibiting concentration) of aflatoxin B1, B2, G1 and G2 to be 1.2, 1.3, 2.2 and 18.0 pg/mL, is the antibody with highest sensitivity among currently reported four aflatoxin antibodies, is used for measuring the total aflatoxin amounts, i.e. the total amounts of the aflatoxin B1, B2, G1 and G2 and has great practical application values.

Disclosed is a novel anti-inflammatory pharmaceutical composition that exhibits potent and selective inhibition of the cycloooxygenase-2 (COX-2) enzyme. The formulation consists of a hops extract that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concentrations that are determined by testing with the William Harvey Whole Blood Assay (WHMA), and falls in the range of 0.011 to 0.2. Such compositions may also optionally contain high levels of alpha acids and low levels of beta acids, some flavonoid compounds, and virtually no essential oils. Such compositions are useful for treating conditions that manifest as inflammatory pain, or are impacted by the COX-2 enzyme. The recited compositions are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic pain with reduced gastric side-effects.

The invention relates to novel application of berberine and derivatives thereof in preparation of medicines, in particular to application of berberine and derivatives thereof in preparation of indole amine 2, 3-dioxygenase IDO inhibitor, belonging to the medicine field. According to IDO inhibition activity detection, reversible inhibition judgment, inhibitor type judgment, Ki value determination and median effective inhibition concentration IC50 determination, the results show that berberine is reversible inhibitor and inhibition constant Ki is 8muM; and jatrorrhizine hydrochloride and palmatine hydrochloride are irreversible inhibitors, and the median effective inhibition concentrations IC50 thereof are respectively 123muM and 126muM. When the berberine and the derivatives thereof disclosed in the invention are used as IDO inhibitors, the application prospect is wide and the IDO inhibitors can be used for treating serious diseases such as cancers, AIDS, Alzheimer diseases, tristimania, cataract and the like with pathological feature of IDO-mediated tryptophan metabolism.

The invention belongs to the field of medicine, and relates to D-configuration polypeptide with high stability and capable of realizing mediated targeting of acetylcholine receptor high-expression cells and crossing corresponding barrier membranes and a nano drug delivery system thereof as well as an application in in-vivo and in-vitro brain targeting and in treatment of brain diseases and the like. Test results indicate that DCDX and the acetylcholine receptor are combined with IC50 to obtain 84.5nM which is stable in serum and tolerates hydrolysis of protease; the model drug carried by DCDX is specifically taken in by the positive cells expressing the acetylcholine receptor and has an ability of crossing the barrier formed by the kind of cells; and the nano drug delivery system made of a DCDX-modified polymer carrier material can deliver the entrapped model drug to the target tissue while the drug effect is remarkably improved. The D-configuration polypeptide DCDX provided by the invention can mediate active targeting of the drug or nano drug delivery system and has a good application prospect in the diagnosis and treatment of multiple diseases.

The invention provides a compound with the structure shown in a formula I, a preparation method of the compound, and an application of the compound as a tyrosine kinase and/or serine-threonine kinase inhibitor. The compound has a good inhibitory action on the activity of multiple kinases, and has an obvious inhibitory effect on tyrosine kinase and/or serine-threonine kinase in biochemical level and cell level in vitro (P is less than 0.05), and the half inhibitory concentration (IC50) for c-Met kinase is commonly below 10<-6>mol/L; and the compound also has an obvious inhibitory effect on proliferation of multiple tumor cells (P is less than 0.05), and the IC50 is respectively below 10<-5>mol/L. The compound with the structure shown in the formula I can be applied to preparing medicines for treating diseases related to protein kinase in organisms. The formula I is shown in the specification.

The invention discloses a method for quickly producing carotenoid by utilizing microaerobic fermentation of rhodobacter sphaeroides. The method comprises the following particular steps that the activated rhodobacter sphaeroides is inoculated to an MMS (methylmercuric sulfate) culture medium; aerobic culture is performed until OD600 (optical density 600) is 0.6-0.8; a culture condition is adjusted to be microaerobic; the carotenoid is induced to be quickly and greatly synthesized; and then extraction and purification are performed. The time for producing the carotenoid by the method is short and only 36h; the yield of thallus is up to 6g/L; the yield and the productivity of the carotenoid are 8.287mg/L and 1911mug/g respectively; the carotenoid has good capacity for removing DPPH (1,1-diphenyl-2-picryl-hydrazyl) radicals; and IC50 (half maximal inhibitory concentration) is about 8mug/mL.

The invention provides a hybridoma cell strain 2D3, a monoclonal antibody to zearalenone secreted by the hybridoma cell strain 2D3 and application of the monoclonal antibody. The hybridoma cell strain 2D3 is preserved in China Center for Type Culture Collection with an accession number of CCTCC No. C201328 and can be used for preparation of a high-titer monoclonal antibody to zearalenone. According to detection results of enzyme linked immunosorbent assay (ELISA), the titer of the monoclonal antibody to zearalenone prepared through purification of mouse ascites can reach 1.5 * 10<5>. The monoclonal antibody to zearalenone has high sensitivity, half maximal inhibitory concentration IC50 of 20 pg/mL to zearalenone and cross reactivity of 4.9%, 3.3% and 3.2% with beta-zearalanel, alpha-zearalanel and beta-zeranol, respectively. The monoclonal antibody to zearalenone can be used for determination of the content of zearalenone.

The invention discloses a compound with an MEK (Mitogen-activated and Extracellular signal-regulated Kinase) inhibiting function as well as a preparation method and application of the compound. The structure of the compound disclosed by the invention is as shown in a formula (I). The preparation method of the compound disclosed by the invention comprises the steps of forming a coumarin ring by adopting a Pechmann reaction mainly and carrying out structural modification of different sites. In the binding experiment of the compound disclosed by the invention and MEK, the binding activity is up to 54.57nM; the anti-proliferation effect IC50 (half maximal inhibitory concentration) value on the melanoma cell A375 is up to 1.23 micrometers; the anti-proliferation effect IC50 value on the colon cancer cell HT-29 is up to 2.13 micrometers; and the activity is higher than that of a positive control U0126. The novel structure type coumarins compound with the MEK inhibiting function shows good MEK binding activity, MEK inhibiting activity, ERK (Extracellular signal Regulated Kinase) pathway inhibiting activity, anti-tumor effect and antiviral effect and has broad application value. The formula (I) is as shown in the specification.

The invention belongs to the medicinal field, and concretely relates to a use of a 8-nitrotryptanthrin compound as an IDO inhibitor. The 8-nitrotryptanthrin compound is a reversible IDO inhibitor, has an inhibition constant Ki of 0.054muM, has in-vitro and cell-based median effective inhibition concentrations IC50 of 0.103muM and 1.80*10<-5>muM respectively, and has an inhibition effectiveness obviously better than a present inhibitor 1-methyltryptophan (Ki of 34muM and IC50 of 340muM). 8-nitrotryptanthrin disclosed in the invention can effectively lower the abnormally-increasing IDO activity in a tumor animal model as the IDO inhibitor, and also has tumor treatment effects comprising tumor growth delaying, tumor volume reduction and in-vitro tumor cell killing. 8-nitrotryptanthrin disclosed in the invention has a wide application prospect, and can be used for treating serious diseases having the IDO mediated tryptophan metabolism approach pathology characteristics, such as cancers, the Alzheimer disease, tristimania, cataract and the like as the IDO inhibitor.

The invention discloses an enzyme linked immunosorbent assay method (ELISA) for detecting the total amount of diamond green and blank diamond green in measurement water sample and aquatic products, characterized in that: the modified compound of amido blank diamond green is synthesized and linked with the protein to produce immunogen and envelope antigen, and the polyclonal antibody of rabbit-anti colorless diamond green is obtained by immuning animal and the concentration range of ELISA standard curve is 0.1-100ng/mL, IC50 is 0.9-2.6ng/mL and the recovery of standard addition is 76.2-95%, the correlation coefficient of ELISA and HPLC is 0.975, n=7; because the cross-reaction rates of the prepared antibody and diamond green are respectively 95.25%, the ELISA can be used for measuring the total amount of the diamond green and blank diamond green without any oxidation step.

Ulcer is a serious oxidative stress induced disease with complex pathologic events including upregulation of H⁺K⁺ ATPase of parietal cell (PC) membrane, damage of mucin layer around PC, PC-DNA damage etc. The polysaccharide (GRPP) fraction and antioxidant extract (GRAOX) of ginger was examined for their ability to inhibit H⁺ K⁺ ATPase. Results indicated that the inhibition of H⁺ K⁺ ATPase activity which causes acidity in the lumen of the stomach, also exhibited better H⁺K⁺ ATPase inhibition (PPI) at the IC50 of 27.2 μg (GRPP) and 16.5 μg GAE (AOX) respectively than the known antiulcer proton pump blocker Lansoprazole (19.3 μg). Further the antioxidant activity in antioxidant extract (GRAOX) by various assay systems was examined such as Reducing power, Free radical scavenging (FRS), DNA and cytoprotection systems etc. GRAOX exhibited concentration dependent reducing power ability at 5-25 g equivalent of phenol. FRS activity with IC₅₀ of 6.8 μg equivalent of phenol etc. At 0.3 μg level GRAOX offered >80% protection to DNA and against FeSO₄-Asc'orbate induced oxidation. The major active phenolic components were identified as Gallic acid/Tannic acid (46%), and Cinnamic acid (51%).

The invention discloses an apple enzyme and a preparation method. The preparation method comprises the following steps: juicing apples, uniformly mixing apple juice with pure water, adding glucose which accounts for 1-5% of the total weight of the obtained raw material mixture into the raw material mixture that the volume percentage of the apple juice is 5-20%, adjusting the pH value to 5.0-7.0, sterilizing, preparing mixed bacteria from the obtained raw material liquid and a pichia pastoris bacterial liquid and a lactobacillus plantarum bacterial liquid in a volume ratio of 1:(1-5), controlling the temperature to 25-35 DEG C, performing primary fermentation for 12-48 hours, controlling the temperature of the obtained primary fermentation solution to 25-35 DEG C by using an acetic bacterial liquid, performing secondary fermentation for 12-36 hours, and sterilizing, thereby obtaining a finished product of the apple enzyme. Compared with a finished product of natural fermentation, the finished product of the apple enzyme disclosed by the invention has a remarkable antibacterial effect on propionibacterium acnes, and the removal rate IC50 of the apple enzyme on DPPH is 0.43%.

The invention relates to a pseudomonas aeruginosa bacterial strain (serial number being CB-4) and a crude toxin preparation method thereof, which belong to the field of applying microorganisms to agricultural plant protection. The strain crude toxin has a strong inhibition effect for weeds including crab grass, amaranthus retroflexus, barnyard grass, green bristlegrass, rhodes grass and the like, and in particular respectively has IC50 reaching 299.25mg.L<-1> and 210.11mg.L<-> to seed germination root stalk length, and has the characteristics of being safe and environment-friendly, harmless to crops and the like.

The present invention discloses a preparation method for increasing antioxidation activity of flammulina velutipes polysaccharide, wherein an enzymolysis control method is adopted to regulate and control molecular weight distribution of flammulina velutipes polysaccharide, flammulina velutipes is sequentially subjected to crushing, impurity removing, hot water extraction, protein removing, concentration and ethanol fractional precipitation separation to obtain the flammulina velutipes polysaccharide, and an enzyme method is adopted to carry out degradation control so as to reduce a molecular weight of the flammulina velutipes polysaccharide to 19000-30000 Da. The flammulina velutipes polysaccharide prepared by using the method is suitable for industrial production, wherein a polysaccharide extraction rate is increased by 2.5-3.5 times compared with a polysaccharide extraction rate of the traditional water extraction method, significant antioxidation activity is provided, IC50 of the flammulina velutipes polysaccharide in a DPPH.radical system is 1.69-2.12 mg/mL, and an ORAC value can be up to 923 mumol Trolox/g.

The invention relates to a rhodamine B ELISA detection method, which belongs to the technical field of ELISA. The invention discloses a rhodamine B ELISA detection method, which comprises the following steps: using synthesized rhodamine B immunogen for immunizing healthy New Zealand rabbits to obtain polyclonal antibodies; and using rhodamine B as standard products; using rhodamine B hapten and OVA coupling materials as coating antigen to establish a rhodamine B indirect ELISA method. The invention provides the fast and efficient detection method for the residual detection on the rhodamine B. Because the polyclonal antibodies are adopted, the cost is low, and in addition, the stability and the repetitiveness are good. The detectability (IC90) is 0.028 ng/mL, the half inhibitory amount (IC50) is 1.3 ng/mL, and the detection range (IC20 to IC80) is between 0.07 and 17.5 ng/mL. Because of high specificity and high compatibility of the immune reaction, high selectivity and high sensitivity can be obtained when the ELISA is used for detecting the rhodamine B.

The invention discloses a method for preparing an antioxidative peptide from skipjack processing by-products. The method comprises the following steps of mixing head sections and tail sections as by-products rich in proteins and a stewing liquor, crushing the mixture, carrying out synchronous three-phase separation to obtain a protein source which can be subjected to direct enzymolysis, adding a flavourzyme into the protein source, carrying out enzymolysis at a pH value of 6.5 at a temperature of 50 DEG C for 4h, purifying the enzymatic hydrolysate by ultrafiltration, activated carbon adsorption and desalination, and carrying out spray drying to obtain peptide powder. Various antioxidant activities of the peptide powder are detected. The peptide powder has good DPPH free radical, superoxide anion free radical and hydroxyl radical removal rates, has IC50 of 3.55mg/ml, 1.39mg/ml and 0.61mg/ml and is an excellent anti-oxidant. The peptide powder is flavescent, has no bitter taste, has a light fishiness taste, has molecular weight (greater than 90.1%) less than or equal to 10000Da, has polypeptide total protein content of 88.6% by dry weight and has ash content of 7.2%.

The antioxidant nutritious various-grain flour is a mixture comprising high gluten wheat flour 70-85 wt%, various-grain flour 10-25 wt%, buckwheat flavone extract 0.1-0.5 wt% and superfine oat bran powder 3-8 wt%. The various-grain flour is produced with buckwheat, oat, kaoliang, corn and/or beans. The antioxidant nutritious various-grain flour has improved taste, raised quality and obvious antioxidant activity, and is detected to have free radical clearance rate IC50 lower than 1.0x10<-2> g and total oxidation resistance higher than 100 mmol/g, 15 times and 5.95 times higher than that of common high gluten wheat flour separately.